372 related articles for article (PubMed ID: 25963426)
1. A Phase I dose-escalation study of afatinib combined with nintedanib in patients with advanced solid tumors.
Gordon MS; Springett GM; Su YB; Ould-Kaci M; Wind S; Zhao Y; LoRusso PM
Future Oncol; 2015; 11(10):1479-91. PubMed ID: 25963426
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of afatinib combined with nintedanib in patients with advanced solid tumours.
Bahleda R; Hollebecque A; Varga A; Gazzah A; Massard C; Deutsch E; Amellal N; Farace F; Ould-Kaci M; Roux F; Marzin K; Soria JC
Br J Cancer; 2015 Nov; 113(10):1413-20. PubMed ID: 26512876
[TBL] [Abstract][Full Text] [Related]
3. Randomized Phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancer.
Molife LR; Omlin A; Jones RJ; Karavasilis V; Bloomfield D; Lumsden G; Fong PC; Olmos D; O'Sullivan JM; Pedley I; Hickish T; Jenkins P; Thompson E; Oommen N; Wheatley D; Heath C; Temple G; Pelling K; de Bono JS
Future Oncol; 2014 Feb; 10(2):219-31. PubMed ID: 24490608
[TBL] [Abstract][Full Text] [Related]
4. A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumours.
Suder A; Ang JE; Kyle F; Harris D; Rudman S; Kristeleit R; Solca F; Uttenreuther-Fischer M; Pemberton K; Pelling K; Schnell D; de Bono J; Spicer J
Eur J Cancer; 2015 Nov; 51(16):2275-84. PubMed ID: 26296295
[TBL] [Abstract][Full Text] [Related]
5. Phase I dose-escalation study of afatinib, an ErbB family blocker, plus docetaxel in patients with advanced cancer.
Marshall J; Shapiro GI; Uttenreuther-Fischer M; Ould-Kaci M; Stopfer P; Gordon MS
Future Oncol; 2013 Feb; 9(2):271-81. PubMed ID: 23414476
[TBL] [Abstract][Full Text] [Related]
6. Phase I trial of afatinib plus vinorelbine in Japanese patients with advanced solid tumors, including breast cancer.
Mukai H; Masuda N; Ishiguro H; Mitsuma A; Shibata T; Yamamura J; Toi M; Watabe A; Sarashina A; Uttenreuther-Fischer M; Ando Y
Cancer Chemother Pharmacol; 2015 Oct; 76(4):739-50. PubMed ID: 26254023
[TBL] [Abstract][Full Text] [Related]
7. A phase I study of volasertib combined with afatinib, in advanced solid tumors.
Machiels JP; Peeters M; Herremans C; Surmont V; Specenier P; De Smet M; Pilz K; Strelkowa N; Liu D; Rottey S
Cancer Chemother Pharmacol; 2015 Oct; 76(4):843-51. PubMed ID: 26349473
[TBL] [Abstract][Full Text] [Related]
8. A phase I, dose-escalation trial of continuous- and pulsed-dose afatinib combined with pemetrexed in patients with advanced solid tumors.
Chu QS; Sangha R; Hotte SJ; Sergenson G; Schnell D; Chand VK; Hirte HW
Invest New Drugs; 2014 Dec; 32(6):1226-35. PubMed ID: 25037863
[TBL] [Abstract][Full Text] [Related]
9. A phase I study of afatinib combined with paclitaxel and bevacizumab in patients with advanced solid tumors.
Spicer J; Irshad S; Ang JE; Enting D; Kristeleit R; Uttenreuther-Fischer M; Pemberton K; Pelling K; Schnell D; de Bono J
Cancer Chemother Pharmacol; 2017 Jan; 79(1):17-27. PubMed ID: 27872953
[TBL] [Abstract][Full Text] [Related]
10. A phase I, dose-escalation study of volasertib combined with nintedanib in advanced solid tumors.
de Braud F; Cascinu S; Spitaleri G; Pilz K; Clementi L; Liu D; Sikken P; De Pas T
Ann Oncol; 2015 Nov; 26(11):2341-6. PubMed ID: 26395347
[TBL] [Abstract][Full Text] [Related]
11. A phase Ib, open-label study to assess the safety of continuous oral treatment with afatinib in combination with two chemotherapy regimens: cisplatin plus paclitaxel and cisplatin plus 5-fluorouracil, in patients with advanced solid tumors.
Vermorken JB; Rottey S; Ehrnrooth E; Pelling K; Lahogue A; Wind S; Machiels JP
Ann Oncol; 2013 May; 24(5):1392-400. PubMed ID: 23293114
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of nintedanib in combination with pemetrexed as second-line treatment of Japanese patients with advanced non-small cell lung cancer.
Daga H; Takeda K; Okada H; Miyazaki M; Ueda S; Kaneda H; Okamoto I; Yoh K; Goto K; Konishi K; Sarashina A; Tanaka T; Kaiser R; Nakagawa K
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1225-33. PubMed ID: 26560486
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4).
Murakami H; Tamura T; Takahashi T; Nokihara H; Naito T; Nakamura Y; Nishio K; Seki Y; Sarashina A; Shahidi M; Yamamoto N
Cancer Chemother Pharmacol; 2012 Apr; 69(4):891-9. PubMed ID: 22071596
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of weekly alternating sequential BIBF 1120 and afatinib for advanced colorectal cancer.
Bouche O; Maindrault-Goebel F; Ducreux M; Lledo G; Andre T; Stopfer P; Amellal N; Merger M; De Gramont A
Anticancer Res; 2011 Jun; 31(6):2271-81. PubMed ID: 21737652
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of nintedanib in Japanese patients with advanced hepatocellular carcinoma and liver impairment.
Okusaka T; Otsuka T; Ueno H; Mitsunaga S; Sugimoto R; Muro K; Saito I; Tadayasu Y; Inoue K; Loembé AB; Ikeda M
Cancer Sci; 2016 Dec; 107(12):1791-1799. PubMed ID: 27627050
[TBL] [Abstract][Full Text] [Related]
16. A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors.
Marshall J; Hwang J; Eskens FA; Burger H; Malik S; Uttenreuther-Fischer M; Stopfer P; Ould-Kaci M; Cohen RB; Lewis NL
Invest New Drugs; 2013 Apr; 31(2):399-408. PubMed ID: 23161335
[TBL] [Abstract][Full Text] [Related]
17. A phase I study to assess afatinib in combination with carboplatin or with carboplatin plus paclitaxel in patients with advanced solid tumors.
O'Brien MER; Sarker D; Bhosle J; Thillai K; Yap TA; Uttenreuther-Fischer M; Pemberton K; Jin X; Wiebe S; de Bono J; Spicer J
Cancer Chemother Pharmacol; 2018 Nov; 82(5):757-766. PubMed ID: 30088048
[TBL] [Abstract][Full Text] [Related]
18. Phase I Study to Assess the Combination of Afatinib with Trastuzumab in Patients with Advanced or Metastatic HER2-Positive Breast Cancer.
Ring A; Wheatley D; Hatcher H; Laing R; Plummer R; Uttenreuther-Fischer M; Temple G; Pelling K; Schnell D
Clin Cancer Res; 2015 Jun; 21(12):2737-44. PubMed ID: 25370464
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors.
Awada AH; Dumez H; Hendlisz A; Wolter P; Besse-Hammer T; Uttenreuther-Fischer M; Stopfer P; Fleischer F; Piccart M; Schöffski P
Invest New Drugs; 2013 Jun; 31(3):734-41. PubMed ID: 23161334
[TBL] [Abstract][Full Text] [Related]
20. A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors.
Gordon MS; Mendelson DS; Gross M; Uttenreuther-Fischer M; Ould-Kaci M; Zhao Y; Stopfer P; Agus DB
Invest New Drugs; 2013 Apr; 31(2):409-16. PubMed ID: 23242861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
